Vicplas International Ltd

Basis of preparation. FY2023–FY2026 are taken from company results announcements; FY2026 figures are unaudited. FY2022 figures come from the FY2026 presentation for profit before tax and adjusted EBITDA, and from S&P Global data via StockAnalysis for other lines; they are flagged as such. Vicplas presents its income statement by nature of expense and does not report gross profit or operating income. Gross profit is therefore replaced with a derived "material margin". EBIT is derived as profit before tax plus finance costs. Adjusted EBITDA is the company's definition: EBITDA excluding unrealised foreign exchange.

Income statement

Table 6.1 — Income statement summary (S$ million)

Notes: FY2022 depreciation and amortisation, finance costs and net profit are from S9 (S&P Global); FY2022 tax and EPS are derived. FY2023 DPS is confirmed as S$0.0045 per share. FY2022 DPS of 0.45 cents is derived from S$2.3m paid in FY2023 divided by 511m shares.

Table 6.2 — Margin profile (%; derived)

Table 6.3 — Cost structure by nature (S$ million; S1, S5)

Table 6.4 — Selected other operating expense and other income items (S$ million; S1, S5)

Income statement commentary.

FY2022 was the cyclical peak: Revenue reached S$130.8m on Covid-era safety-stock ordering by medtech customers.

FY2023–FY2024: destocking: Medical revenue fell 30.3% in FY2024 as customers right-sized inventories. Group revenue dropped to S$102.4m. Employee costs were cut 12.4%, but depreciation and amortisation rose 9.1% as the Changzhou extension and Juarez came on stream.

FY2025–FY2026: revenue recovery without operating leverage: Revenue grew 13.1% and then 10.0%. Material margin was stable at about 53% (derived). Yet adjusted EBITDA fell from S$8.5m to S$6.8m in FY2026. The causes were:

• employee costs up 9.9% to S$43.4m on headcount and overtime;

• other operating expenses up 12.2%, with freight up 65%;

• depreciation and amortisation up 9.1% on the first full year of Juarez depreciation;

• tooling income down 12%;

• impairment of financial assets up to S$0.74m, including S$0.28m against a related party (S1, Note 5).

The inflection is fixed-cost absorption, not pricing: The Juarez plant recorded its first full year of operating costs in FY2026 while producing only at small scale. Management also cites higher input prices linked to the Middle East conflict.

Tax: Income tax expense persists despite group losses (S$0.66m in FY2026), because profitable entities, notably Vicplas Pipes, and the Mexican subsidiary under its tax regime incur tax that cannot be offset against losses elsewhere. This tax leakage widens the gap between pre-tax and net losses.

Earnings quality: Unrealised FX losses (S$0.84m in FY2026) are excluded from adjusted EBITDA. The S$1.12m FX gain in FY2024 flattered that year's reported numbers.

Balance sheet

Table 6.5 — Balance sheet (S$ million, as at 31 July)

Sources: FY2023–FY2026 from S1 and S5. FY2022 lease liabilities, PP&E incl. ROU, receivables plus contract assets and goodwill/intangibles are from S9. FY2022 borrowings and equity are from the FY2022 results announcement. Short-term investments of S$0.6–1.4m reported by S9 in some years are excluded from cash here.

Balance sheet commentary.

Leverage has risen every year since FY2023: Net debt including leases rose from S$9.0m in FY2023 to S$42.5m in FY2026; equity eroded by S$10.9m over the same period through losses and dividends.

Refinancing exposure is concentrated: Bank borrowings of S$35.3m at 31 July 2026 are 80% current: S$28.2m is repayable within one year or on demand (S1, Note 12).

Security and guarantees: Borrowings are secured by a legal mortgage over leasehold land with a carrying value of about S$7.65m, plus corporate guarantees from the Company of S$28.9m and US$2.215m.

Liquidity is thin: Cash of S$5.9m covers less than a quarter of current borrowings.

Inventory jumped 32% in FY2026: to S$24.4m. Management attributes this to advance procurement to manage Middle East-related resin volatility in pipes and to higher activity.

Contract assets fell: from S$15.4m to S$12.1m as customer safety-stock requirements normalised.

Goodwill is immaterial: at about S$1.1m within intangibles. However, the company flags impairment testing of medical-segment PP&E, right-of-use assets and goodwill as a key estimate (S1, Note 2.2). With the segment loss widening, this is a latent risk to equity.

Cash flow

Table 6.6 — Cash flow summary (S$ million)

Sources: FY2023–FY2026 from S1 and S5; FY2022 from S9. The FY2023 OCF of S$18.04m is per the FY2024 filing comparative; S9 shows S$17.88m (minor discrepancy).

Cash flow commentary.

FY2023 was the last year of material free cash generation: (S$12.6m), helped by a S$8.3m receivables release as revenue fell.

• Free cash flow has been negative for three years since then, a cumulative −S$17.6m before leases (derived). This was financed almost entirely by new bank debt (net S$24.9m raised FY2024–FY2026) and by suspending the dividend.

FY2026 operating cash flow of S$1.4m was weak: against adjusted EBITDA of S$6.8m. Working capital absorbed S$3.7m, mainly from receivables (−S$6.3m) and inventories (−S$5.1m), partly offset by payables (+S$4.2m) and contract assets (+S$3.3m). Interest of S$1.2m and tax of S$1.0m were also paid.

Capex has normalised: at about S$5.4m (4.3% of revenue) after the FY2024 Juarez peak of S$14.3m. Management states capex fell in FY2026 because Mexico spending declined.

Ratios

Table 6.7 — Return, leverage and efficiency ratios (derived)

ROIC methodology: NOPAT = EBIT × (1 − 17% Singapore statutory rate) when EBIT is positive, and EBIT untaxed when negative. Invested capital = equity + total debt incl. leases − cash.

Table 6.8 — Working capital days (derived from S1, S5; cost base = materials + purchases − inventory change)

Ratio commentary. Every leverage and coverage metric has deteriorated for three consecutive years. Net debt to adjusted EBITDA of 6.2x and EBITDA interest cover of 3.4x would breach typical covenant thresholds (3.0–3.5x net leverage) if such covenants apply. Covenant terms are not publicly disclosed, and the company has not reported any breach. The cash conversion cycle of roughly 190 days is long for a manufacturer. It reflects over-time revenue recognition and contract assets in medical devices, extended contractor credit terms in pipes, and buffer inventory. Returns on capital have fallen below any reasonable cost of capital since FY2024.

Management guidance.

• Revenue growth is expected in the next reporting period but tempered by geopolitical, supply-chain and tariff risks.

• Medical revenue should improve as projects are commercialised and Juarez contributes more.

• The medical segment result will remain constrained in the short term.

• Pipes will stay disciplined on pricing, credit and costs, focusing on green materials.

• No quantified guidance is given.

Consensus growth expectations. None available (no coverage).

Bull case:

1. Operating leverage from installed capacity. Juarez (S$29.7m of assets) and the Changzhou extension are largely built. Capex has already fallen to S$5.4m (4.3% of revenue). Each incremental project should flow through at high incremental margins. Medical revenue recovering to the FY2022 level of S$92.6m, with costs now largely fixed, could return the segment to break-even or better.

2. Customer validation and pipeline. The 2025 Global Supplier of the Year award, five micro-moulding parts awarded for Juarez, three Juarez projects in production (two incremental), and cell and gene therapy demand in Singapore all point to a growing funnel.

3. Asset backing and pipes cash engine. At 0.50x book and about 3.3x EV-to-pipes segment result (S$33.7m market cap versus S$10.2m pipes result), the market assigns little or negative value to Forefront. Pipes alone could arguably support much of the enterprise value, given S$12–15bn per year of Singapore civil engineering and institutional demand.

Bear case:

1. Balance-sheet stress before payback. Net debt/adjusted EBITDA of 6.2x, S$28.2m of debt due within 12 months, negative free cash flow for three years and cash of only S$5.9m. Further delays at Juarez could force asset sales, an equity raise at a deep discount to NAV, or reliance on controlling-shareholder support.

2. Structural sub-scale in a consolidating CDMO market. Integer's 17.3% adjusted operating margin at US$1.85bn of revenue shows the scale economics Forefront lacks. Ramp delays and the UK site's decline suggest execution risk across a footprint spread over five plants and three continents for under S$80m of revenue.

3. Pipes cyclicality. FY2026's 25% pipes growth coincided with record public residential demand in 2025. BCA forecasts public residential demand down about 30% in 2026. Pipes margin normalisation would remove the group's only profit source.

Key catalysts and monitorables (next 12 months):

• FY2026 Annual Report (around Nov 2026): audited numbers; going-concern language; borrowing covenants; FY2026 shareholding statistics.

• 28th AGM (expected late Nov 2026): board renewal; any capital-management resolutions.

• 1H FY2027 results (expected Mar 2027): medical segment result versus −S$5.65m in 1H FY2026; Juarez project count and revenue commentary.

• Refinancing or extension of S$28.2m of current borrowings.

• "In China for China" order recovery and China-billed revenue trend.

• Resin and input-cost trends linked to Middle East developments.

• Further CTX Treuhand / Venner shareholding filings that could signal ownership changes.

• Any impairment of medical-segment assets.

Concluding analyst verdict.

Vicplas International is a classic small-cap "sum-of-the-parts versus balance sheet" situation. One half of the group is a steady, high-return Singapore building-products business. Vicplas Pipes produced a S$10.2 million segment result in FY2026 at a 21% margin, supported by local leadership, Green Mark certification and a construction cycle that BCA expects to remain elevated through 2030.

The other half is a medical device CDMO that executed a sensible strategy, regional manufacturing optionality for OEMs, at a scale too small to absorb its cost. Forefront Medical has grown revenue at 12% a year since FY2018. However, after building out Changzhou and Juarez it lost S$8.7 million at the segment level in FY2026 on revenue of S$79.1 million. The result is three consecutive group losses, a dividend suspended since FY2024, net debt that has quadrupled since FY2023, and 80% of bank borrowings falling due within a year.

The equity, at about S$34 million and half of book value, already discounts much of this. Upside depends on a single, observable variable: whether Juarez and the new Singapore cleanroom projects can lift medical revenue towards the FY2022 peak of S$93 million fast enough to absorb fixed costs before lenders or shareholders lose patience. Management's own language, with segment results "constrained in the short term" and acknowledged project delays, argues against expecting that inflection within FY2027. The controlling shareholder's commitment remains the key unquantified backstop.

On balance, the risk/reward is speculative and execution-dependent. It does not suit income or quality-focused mandates. Thin liquidity, no sell-side coverage and limited disclosure, notably on Mexico revenue and debt covenants, add to the discount and should temper position sizing. Evidence of sequential medical-loss reduction in 1H FY2027 and a clean refinancing would be the triggers for a more constructive view.